GSK boasts 83% efficacy for RSV vaccine candidate
“These are truly exceptional results,” says the chief scientific officer at the company, which is expected to seek regulatory approval later this year. One Sydbank analyst comments on the news. (Updated)
by marketwire, translated by daniel pedersen
British pharmaceutical group GSK’s vaccine candidate against respiratory syncytial virus, or RSV, demonstrated 83% efficacy overall in a recent study, Bloomberg News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to submit RSV vaccine for FDA approval in fall
For subscribers
